Most people in Missouri who are curious about newer depression treatments stop at the same place. Not at the science, and not at the side effects. They stop at a belief about insurance, usually one they never checked.
That belief carries real weight. This summer our poll asked 443 adults, Missourians and their neighbors in nine states, to rate insurance as a reason to try, or skip, ketamine or esketamine for depression. For 65 percent, it would settle things or weigh heavily. When nearly two thirds of people are letting coverage steer, a wrong assumption about coverage can quietly end the conversation before it starts.
Here are five common beliefs, checked. The poll figures below are final.
Myth one: "If it is new, insurance will not touch it."
This is the most common assumption, and it deserves a closer look. Spravato, an esketamine nasal spray, is not experimental. Its FDA approval targets depression that has outlasted adequate trials of other antidepressants. That approval is precisely what gives insurers a basis to cover it.
Coverage is not automatic, and plans differ. Many require prior authorization and a record of what you have already tried. But "new" and "uncovered" are not the same word. The only way to know about your plan is to ask your plan.
The myth holds a grain of truth for ketamine used outside that approval, like clinic IV drips or home programs, which is more often paid out of pocket. Keep the two separate when you ask questions.
Myth two: "Only people with good employer insurance get these treatments."
This picture of who is looking for depression care does not match what we heard. When respondents told us how they are covered, commercial insurance was the most common answer at 39 percent, with Medicaid just behind at 37 percent. Medicare trailed at 23 percent, while 9 percent lacked insurance and 5 percent used TRICARE. Respondents could pick more than one, which is why the list adds past 100.
In Missouri, Medicaid is called MO HealthNet, and many members receive benefits through a managed care health plan. If that is you, phone the plan about esketamine, prior authorization, and in-network sites rather than assuming you are shut out. Uninsured readers can ask clinics about assistance or manufacturer programs.
Myth three: "Prior authorization means they are trying to say no."
Paperwork feels like a wall, especially when you are already exhausted. But prior authorization is usually the plan asking for evidence that the treatment matches what it was approved for. For esketamine, that commonly means documentation that other antidepressants were tried without enough improvement.
Interestingly, most of the people we surveyed seem to understand this tradeoff instinctively. Offered insured care with more steps or cash-pay care with fewer, just over half chose insurance. Twenty-three percent chose to pay themselves, and the remaining 26 percent were undecided. Hoops are a hassle. They are not a verdict.
What helps: a doctor who knows your history and is willing to document it clearly. That leads directly to the next myth.
Myth four: "I need to figure out coverage on my own before I bring it up."
You can do some homework first, and it helps. But you do not need to arrive with every answer. Your doctor and the treatment site are part of the coverage process. The prescriber typically submits the prior authorization. The certified site often verifies benefits.
The survey suggests this is also where people's trust already sits. The most persuasive voice for respondents was their own doctor, at 74 percent, compared with 18 percent for family or friends and 2 percent for advertising, and 56 percent would go to a primary doctor first.
So bring the question to the person you already trust. Say plainly that coverage will matter to you. That is useful information, not a distraction.
Myth five: "Paying cash is always the faster, easier way."
Sometimes it is. Sometimes it is not. Self-pay can remove the authorization step, but it does not remove the medical evaluation, and for esketamine it does not remove the structure of care. Every dose still takes place at a certified clinic, where you wait under watch for a couple of hours before a friend drives you home. Missourians weighing the two can see how Brain Recovery Centers lays out esketamine costs under insurance and self-pay for readers comparing the two. Those logistics are the same whether a plan pays or you do.
Self-pay also tends to steer people toward options outside the FDA-approved framework, which may be fine for some and not for others. Our poll found FDA approval weighing heavily, or decisively, with 59 percent of respondents. If approval matters to you, make sure the thing you are paying for is the thing you think it is.
What is true, and useful
Set the myths aside and a few practical facts remain:
- Coverage for esketamine exists on many plans, often with prior authorization.
- Medicaid members are a large share of the people seeking this kind of care, not an afterthought.
- Your doctor is both the person you are most likely to trust and a key part of getting coverage approved.
- Location matters. After insurance, the attribute respondents most often ranked in their top two was being close to home, at 43 percent. In a state as spread out as Missouri, ask how far the nearest in-network site is before you commit.
The limits of this article
This is a guide to insurance beliefs, drawn from market research. It is not medical advice and not a promise of coverage or results. Esketamine has one approved use, and your own clinician decides if you fit it. Plan rules change, so always confirm with your insurer.
If what you are feeling right now is more urgent than any of this, reach out today. Any Missourian can dial or text 988, and that line, the Suicide and Crisis Lifeline, stays open around the clock, at no cost, with no insurance card needed.
Methodology
Our source for Missouri readers is Pollfish survey 395586438, which Pollfish panelists could answer until the June 23, 2026 cutoff; it returned 443 completes from working-age adults, 18 through 64, in Indiana, Missouri, Iowa, Kansas, Minnesota, Illinois, Nebraska, Wisconsin, Ohio or Oklahoma. Payer items allowed several answers, so those totals pass 100. Each figure is a validated whole-sample share. Missouri readers should know the publisher ordered this research and funded it.